摘要
目的探讨安罗替尼对非小细胞肺癌患者肺功能的影响及安全性分析。方法选取2018年12月~2019年12月九江市第三人民医院收治的48例非小细胞肺癌患者作为研究对象,采用随机数字表法分为观察组(24例)和对照组(24例),对照组患者采用紫杉醇白蛋白联合顺铂化疗治疗,观察组在对照组基础上采用安罗替尼治疗。比较两组患者的治疗效果、肺功能及不良反应发生情况。结果观察组治疗总有效率为91.67%,高于对照组的75.07%,差异有统计学意义(P<0.05)。治疗前两组用力肺活量(FVC)、第1秒用力呼气容积(FEV1)及FEV1/FVC水平比较,差异无统计学意义(P>0.05);治疗后两组FVC、FEV1、FEV1/FVC水平高于治疗前,且观察组FVC、FEV1、FEV1/FVC水平高于对照组,差异有统计学意义(P<0.05)。观察组不良反应总发生率为9.10%,低于对照组的25.00%,差异有统计学意义(P<0.05)。结论安罗替尼治疗非小细胞癌可有效改善患者的肺功能,控制肿瘤进展,促进病情恢复,且安全性较高。
Objective To investigate the effect and safety of Amlotinib on lung function in patients with non-small cell lung cancer.Methods A total of 48 patients with non-small cell lung cancer treated in the Jiujiang Third People′s Hospital from December 2018 to December 2019 were selected as the research objects,and divided into the observation group(24 cases)and the control group(24 cases)by random number table method.The control group was treated with Paclitaxel Albumin combined with Cisplatin chemotherapy,and the observation group was treated with Amrotinib on the basis of control group.The therapeutic effect,lung function and the incidence of adverse reactions were compared between the two groups.Results The total effective rate of the observation group was 91.67%,which was higher than that of the control group(75.07%),and the difference was statistically significant(P<0.05).Before treatment,there were no significant differences in forced vital capacity(FVC),forced expiratory volume in the first second(FEV1)and FEV1/FVC between the two groups(P>0.05).After treatment,the levels of FVC,FEV1 and FEV1/FVC in the two groups were higher than before,and the levels of FVC,FEV1 and FEV1/FVC in the observation group were higher than those in the control group,with statistical significances(P<0.05).The total incidence of adverse reactions in the observation group was 9.10%,which was lower than that in the control group(25.00%),and the difference was statistically significant(P<0.05).Conclusion Anlotinib in the treatment of non-small cell carcinoma can effectively improve the lung function of patients,control tumor progression,and promote the recovery of the disease,with high safety.
作者
储节胜
徐冠军
时毓
丁智
傅敬忠
CHU Jie-sheng;XU Guan-jun;SHI Yu;DING Zhi;FU Jing-zhong(Department of Oncology,Jiujiang Third People′s Hospital,Jiangxi Province,Jiujiang 332000,China)
出处
《中国当代医药》
CAS
2021年第17期100-102,共3页
China Modern Medicine
基金
江西省科技支撑计划项目(20142BBG70117)。
关键词
非小细胞肺癌
安罗替尼
紫杉醇白蛋白
顺铂化疗
肺功能
安全性
Non-small cell lung cancer
Anlotinib
Paclitaxel albumin
Cisplatin chemotherapy
Lung function
Security
